Abstract Recent gene expression profiling studies have identified five breast cancer subtypes, of which the basallike subtype is the most aggressive. Basal-like breast cancer poses serious clinical challenges as there are currently no targeted therapies available to treat it. Although there is increasing evidence that these tumors possess specific sensitivity to cisplatin, its success is often compromised due to its dose-limiting nephrotoxicity and the development of drug resistance. To overcome this limitation, our goal was to maximize the benefits associated with cisplatin therapy through drug combination strategies. Using a validated kinase inhibitor library, we showed that inhibition of the mTOR, TGFbRI, NFjB, PI3K/AKT, and MAPK pathways sensitized basal-like MDA-MB-468 cells to cisplatin treatment. Further analysis demonstrated that the combination of the mTOR inhibitor rapamycin and cisplatin generated significant drug synergism in basal-like MDA-MB-468, MDA-MB-231, and HCC1937 cells but not in luminal-like T47D or MCF-7 cells. We further showed that the synergistic effect of rapamycin plus cisplatin on basal-like breast cancer cells was mediated through the induction of p73. Depletion of endogenous p73 in basal-like cells abolished these synergistic effects. In conclusion, combination therapy with mTOR inhibitors and cisplatin may be a useful therapeutic strategy in the treatment of basal-like breast cancers.
Introduction
The recent identification of novel breast cancer subtypes with distinct biological features promises the development of more specific, more effective, and less toxic therapies. Based on gene profiling, breast cancer can be categorized into five different subtypes with distinct clinical outcomes: luminal A, luminal B, human epidermal growth factor receptor-2 (HER2)-overexpressing, normal-like, and basallike breast cancer [1, 2] . Of particular importance is the basal-like breast cancer subtype, which accounts for 15-20% of breast cancers overall and confers a markedly poor prognosis compared to other subtypes. The majority of basal-like breast cancers exhibit a ''triple-negative'' phenotype, characterized by the lack of expression of the estrogen receptor (ER) or the progesterone receptor (PR) and a lack of HER2 amplification. They also often have a high frequency of p53 mutations [3, 4] . Due to the lack of expression of the ER, PR, and HER2 receptors, patients with basal-like breast cancers usually do not respond to hormonal therapy, trastuzumab, or chemotherapy [5, 6] . Consequently, the mortality rate of patients with basal-like breast cancer is relatively high compared to patients with non-basal subtypes [1] .
Cisplatin, a chemotherapeutic agent that is not commonly used for breast cancer, became known as a potential tool in the management of basal-like breast cancer based on evidence that breast cancer cells that have a basal-like phenotype possess a selective sensitivity towards cisplatin when compared to other chemotherapeutic agents. A variety of evidence suggests that basal-like breast cancers may share defects in BRCA1-associated pathways in which DNA repair mechanisms have been compromised [7] . Indeed, recent clinical studies have demonstrated the clear advantage of cisplatin over other chemotherapeutic agents in the treatment of basal-like breast cancer [8, 9] . Nevertheless, dose-limiting toxicity, including nephrotoxicity, neurotoxicity and ototoxicity have prevented the widespread use of cisplatin in breast cancer therapy.
To address this problem, we developed a high-throughput screening assay to rapidly identify new therapeutic agents that are synergistic with cisplatin in basal-like breast cancers. Using a small chemical library that targets some of the most relevant oncogenic pathways in basal-like breast cancer, we showed that inhibition of mTOR by rapamycin led to the development of synergy with cisplatin in basal-like breast cancer cells. We found that this synergistic effect was mediated in part through the induction of p73. This finding suggests that rapamycin and cisplatin may be a rational combination for targeted therapy in the treatment of refractory basal-like breast cancers.
Materials and methods

Cell lines and cell culture
The human breast carcinoma cell lines MCF-7, T47D, MDA-MB-231, MDA-MB-468, and HCC1937 were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 lg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA) at 37°C in an environment containing 5% CO 2 .
MTT cell proliferation assay Dose-response curves and IC 50 values were determined using the methyl thiazolyl tetrazolium (MTT) cell viability assay as described previously [4, 10] . Cells were seeded in 96-well plates for 24 h at a density of 5 9 10 3 cells/well. Concentrated (100 mM) solutions of cisplatin were prepared in DMSO immediately before use. Cell masses that were viable after 3 days of drug exposure were determined by cell-mediated MTT reduction. Cell growth and drug activity was determined by measuring absorbance at 550 nm using a TECAN Infinite F200 plate reader (Männedorf, Switzerland).
Construction of the IC 50 mean graph
The IC 50 mean graph was constructed as described by the Developmental Therapeutics Program of the National Cancer Institute (http://dtp.nci.nih.gov). The mean graph consists of positive (more sensitive) and negative (less sensitive) ''delta'' values, which are generated from a set of IC 50 via a three-step calculation: (1) the IC 50 values for each cell line against the tested compound are converted to log(IC 50 ) values; (2) for each tested compound, the log(IC 50 ) values are averaged; and (3) the individual IC 50 value is then subtracted from the average to generate the delta value. Positive delta values project to the right of the vertical line and represent cellular sensitivity to the test agent that exceeds the mean value. Negative values project to the left of the vertical line. They represent a lower than average sensitivity to the test agent.
Library screening
The InhibitorSelect TM chemical library, which consists of 160 well-characterized, cell-permeable inhibitors, was purchased from EMD Chemicals, USA. MDA-MB-468 cells in the logarithmic growth phase were seeded in a 96-well plate at a density of 5 9 10 3 cells/well. Each compound was added to reach a final concentration of 1 or 10 lM in the absence or presence of 1 lM cisplatin. Plates were incubated for 72 h at 37°C. Cell proliferation was examined using MTT assay. Combination treatments that induced growth inhibition to a greater extent than the same doses used alone (P \ 0.05; Student's t-test) were considered to be ''hits''.
Drug combination analysis
Drug combination analysis was performed by using the method described by Chou and Talalay [11] . Briefly, cells were seeded at a density of 5 9 10 3 cells/well in 96-well plates and treated with 1-100 lM cisplatin and compound alone or in combination for 72 h. Cell proliferation was measured by MTT assay. Multiple drug dose-effect calculations and the combination index plots were generated using Calcusyn 2.1 software (Biosoft, Cambridge, UK).
Combination index (CI) values of \1, =1, and [1 indicate synergism, an additive effect, and antagonism, respectively.
Apoptosis assays
Quantitation of apoptosis by annexin V/propidium iodide (PI) staining was performed using a BD ApoAlert annexin V-FITC Apoptosis Kit (BD Biosciences, USA) according to the manufacturer's instructions. Both floating and attached cells were collected 72 h after drug treatment. Cells were analyzed on a FACSCalibur flow cytometer using CellQuest Pro software (version 5.1.1; BD Biosciences, USA).
Quantitative PCR analysis
Total RNA from cells was extracted using a Qiagen RNA isolation kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. First-strand cDNA was synthesized using random hexamer primers and the SuperScript II system for RT-PCR (Invitrogen, Carlsbad, USA). Gene expression levels were measured by quantitative PCR (qPCR) using the iQ SYBR Green Supermix reagent and a Biorad iQ5 real-time PCR detector system (Bio-Rad, Richmond, CA, USA). Data analysis was performed using Biorad iQ5 Optical System Software V1.0. The specific forward and reverse primer sequences were shown in Supplementary Table 1. The conditions for all qPCR reactions were as follows: 3 min at 94°C followed by 40 s at 94°C, 40 s at 60°C, and 25 s at 72°C for 40 cycles.
Protein isolation and western blot analysis
Protein lysates from cells were extracted in ice-cold lysis buffer (0.75% NP-40, 1 mM DTT, and protease inhibitors in PBS). Total protein (25 lg) was subjected to SDS-PAGE followed by immunoblotting with the following antibodies: p73 (Calbiochem, USA); pS6K (Cell Signaling Technology, USA); S6K (Cell Signaling Technology, USA); mTOR (Cell Signaling Technology, USA); and b-tubulin (Santa Cruz Biotechnology, USA).
Lentiviral production and infection
shRNA lentiviral constructs were created by transferring the U6 promoter-shRNA cassette into a lentiviral backbone, and high-titer lentiviral stocks were generated by co-transfection with packaging vectors into 293T cells, as described previously [3, 4, 10] . The shRNA target sequence for TAp73 was 5 0 -GGATTCCAGCATGGACGTCTT-3 0 . This sequence is found within exon 3 of the p73 gene. Therefore, this shRNA does not target DNp73 [4] .
Results
Selective sensitivity of basal-like breast cancer to cisplatin
To gain an overview of the selectivity of chemotherapeutic agents on breast cancer cells, we compared their anti-proliferative properties in a panel of basal-like and luminal-like breast cancer cell lines that had been previously validated through gene profiling [12] . All cells were treated with increasing concentrations of cisplatin, paclitaxel, or doxorubicin for 72 h, and growth inhibition was then measured by the MTT assay. Figure 1 summarizes the results from these breast cancer cell lines. The results show that basal-like breast cancer cells demonstrated selective sensitivity to cisplatin. (Fig. 1a, b ; Supplementary Table 2 ).
Small chemical library screening identified rapamycin as synergistic agent when used with cisplatin
To identify small molecules that enhance the sensitivity of basal-like breast cancer cells to cisplatin, a cell-based highthroughput screen was performed using MDA-MB-468 cells and a small chemical library consisting of 160 previously validated specific inhibitors. The screening was conducted in 96-well plates containing 1 lM cisplatin to which test compounds were added at concentrations of 1 or 10 lM. Cell viability was measured 72 h later by MTT assays. Combinations of the treatments that induced growth inhibition higher than that of the same doses used alone (P \ 0.05; Student's t-test) were considered to be ''hits''.
The molecules identified in this screen included rapamycin, [3- 
The structures of these compounds are shown in Fig. 2 . The molecular targets of these compounds are listed in Table 1 .
The six compounds that we identified are specific inhibitors of the mTOR, TGF-b, EGFR, NFjB, PI3K/AKT, and MAPK pathways, which have previously been reported to be upregulated in basal-like breast cancers [13] [14] [15] [16] [17] . However, when tested for synergism with cisplatin at a fixed concentration ratio, only rapamycin demonstrated synergism in MDA-MB-468 cells. The mean combination index (CI) at the ED 50 , ED 75 , and ED 90 of the 10:1 cisplatin:rapamycin combination was 0.52 ± 0.06, where a combination index of \1 denotes synergy according to the isobologram method developed by Chou and Talalay [11] . The remaining compounds (LY364947, AG1478, BAY11-7082, LY294002, and SB203580) show mainly additive effects (i.e., CIs close to 1) with cisplatin in MDA-MB-468 cells, reflecting the narrow range of concentrations over which they enhanced cisplatin-induced cell killing (Table 1) .
Specific synergistic effects of rapamycin and cisplatin in basal-like breast cancer cells Next, we studied the synergistic effects of cisplatin and rapamycin in a panel of breast cancer cell lines with either basal-like or luminal-like phenotypes. The anti-proliferative effect of the combination treatment was evaluated via MTT assays, and drug interaction was assessed by the isobologram method as described in the previous section. The results demonstrated that the combination of rapamycin and cisplatin exhibited selective synergistic effects in the basal-like MDA-MB-468, MDA-MB-231, and HCC1937 cells, but not in the luminal-like T47D or MCF-7 cells ( Fig. 3 ; Table 2 and Supplementary Fig. 1 ).
Rapamycin specifically enhances cisplatin-induced apoptosis in basal-like breast cancer cells
To ensure that the lack of synergistic effects of rapamycin and cisplatin observed in luminal-like cells was not due to a general lack of sensitivity of luminal-like cells to cisplatin, we compared the apoptotic effects induced by cisplatin and rapamycin alone and in combination in MDA-MB-231, MDA-MB-468, and T47D cells using an equally potent dose (IC 50 dose) of cisplatin. All cell lines exhibited similar amounts of apoptosis following treatment with their respective IC 50 dose of cisplatin. Interestingly, when these cell lines were treated with the combination of cisplatin and rapamycin, enhanced apoptotic effects were observed in the MDA-MB-231, MDA-MB-468, and HCC1937 cells but not in the T47D and MCF-7 cells ( Fig. 4a ; Supplementary Figure 2) . Furthermore, the synergistic effects of rapamycin observed in MDA-MB-231 cells were further enhanced by sequential treatment with rapamycin for 6 h followed by cisplatin (data not shown). These results demonstrated that rapamycin is capable of sensitizing basal-like breast cancer cells to cisplatin, suggesting that the synergistic effects of rapamycin and cisplatin may be mediated through a common pathway.
Rapamycin sensitizes basal-like cells to cisplatin through p73 upregulation
Previous studies have shown that the inhibition of mTOR by rapamycin up-regulates the transactivating isoform of p73 (TAp73) in breast cancer cells [18] . Our group and others have also demonstrated that TAp73 is overexpressed in a subset of triple-negative breast tumors, and TAp73 is required for cisplatin sensitivity in basal-like breast cancer cells [4] . Based on these findings, we sought to determine if the synergistic effects of the combination of rapamycin and cisplatin could be explained by enhanced activation of the p73 pathway.
To test this notion, MDA-MB-231, MDA-MB-468, HCC1937, MCF-7, and T47D cells were treated with their respective IC 50 dose of cisplatin and 100 nM of rapamycin, alone or in combination, for 48 h. mTOR inhibition was confirmed using phospho-S6K as a marker of mTOR Fig. 4b; Supplementary Figure 2) , likely due to the phosphorylation and stabilization of TAp73 following the DNA damage response, as reported previously [19, 20] . Treatment of cells with rapamycin alone also induced a significant amount of TAp73 protein expression in basallike MDA-MB-231, MDA-MB-468 and HCC1937 cells. This induction, however, was absent in the luminal-like T47D and MCF-7 cells ( Fig. 4b; Supplementary Figure 2) . Further enhancement of TAp73 protein expression was also observed only in MDA-MB-231, MDA-MB-468, and HCC1937 cells following the treatment of cells with cisplatin-rapamycin combination. Again, this enhancement was absent in T47D and MCF-7 cells. Thus, the induction of TAp73 by rapamycin in breast cancer cell lines helps explain the synergism observed between rapamycin and cisplatin.
Next, we investigated if the induction of TAp73 in MDA-MB-231 and MDA-MB-468 cells following treatment of rapamycin was due to transcriptional activation of the p73 gene. We quantified the mRNA levels of TAp73 via TAp73-specific qPCR. No significant changes in the mRNA levels of TAp73 were observed following treatment of cells with cisplatin and/or rapamycin ( Supplementary  Figure 3) , suggesting that the induction is likely to be regulated by post-translational events.
Next, we evaluated the expression of the two potent proapoptotic BH3-only proteins, PUMA and NOXA (which have been identified as TAp73 target genes), using qPCR [21, 22] . As expected, treatment of cells with cisplatin for 48 h induced mRNA expression of PUMA and NOXA in MDA-MB-231, MDA-MB-468, and T47D cells, which correlates with the TAp73 induction in these cells observed following cisplatin treatment (Fig. 4c) . When cells were treated with the cisplatin-rapamycin combination, the p73 is required for the synergistic effects of rapamycin and cisplatin in basal-like breast cancer cells
To further evaluate if p73 was the effector of the synergistic effects observed between rapamycin and cisplatin in basallike breast cancer cells, we generated a series of isogenic cell lines that were depleted for TAp73 by stably expressing an shRNA species that specifically targets human TAp73. Figure 5 shows efficient knock-down of all TAp73 isoforms in MDA-MB-231 and MDA-MB-468 cells following shRNA treatment.
As expected, treatment with cisplatin alone induced a significant amount of apoptosis in MDA-MB-231 and MDA-MB-468 vector control cells (Fig. 5) . Consistent with our previous observations, these apoptotic effects were further enhanced in the presence of rapamycin. In stark contrast, depletion of TAp73 completely abrogated the enhanced effects of apoptosis in rapamycin-cisplatin treatment (Fig. 5 ). This result was further supported by the isobologram analysis, which showed a lack of synergism of rapamycin-cisplatin treatment in the TAp73-depleted cells ( Fig. 6; Supplemental Figure 4) . Together, these results suggest that TAp73 is required to exert the synergistic effects of rapamycin and cisplatin in basal-like breast cancers, and the combination of mTOR inhibitors and cisplatin may be a useful therapeutic strategy in the treatment of basal-like breast cancers.
Discussion
Through gene profiling, breast cancers can be classified into five molecularly distinct subtypes: luminal A, luminal B, HER2?, basal-like, and normal breast cancers. The basal-like subtype, which represents 15-20% of breast cancers, has been extensively studied in recent years due to its association with poor patient survival [1, 2, 17, 23] . Several lines of evidence suggest a link between basal-like breast cancers and BRCA1 deficiency [13, 24, 25] . In most cases, the clinical features and outcomes of women with sporadic basal-like breast cancers are broadly similar to those with BRCA1-related cancers [13, [26] [27] [28] [29] [30] [31] . The majority of BRCA1-associated cancers are also ''triplenegative'' (ER-, PR-, and HER2-negative) and express basal cytokeratins and other markers that are commonly seen in basal-like breast cancers (e.g., p53, P-cadherin, and EGFR) [13] . Gene expression profiling has also demonstrated that BRCA1-associated cancers segregate strongly with basal-like breast cancers [2, 28, 32, 33] . Although somatic BRCA1 gene mutations are uncommon in sporadic basal-like cancers, these tumors have been shown to have a dysfunctional BRCA1 pathway due to promoter methylation of the BRCA1 gene and/or transcriptional inactivation of the BRCA1 pathway [13, 24, 25] . The fundamental similarities between hereditary BRCA1-related breast cancers and basal-like cancers suggest that strategies targeting the dysfunctional BRCA1 pathway may be effective in the treatment of basal-like breast cancers. There is increasing evidence that the DNA repair defects in BRCA1-related cancers confer sensitivity to platinum-based chemotherapy drugs [33] [34] [35] [36] [37] . Indeed, recent clinical studies have found that sporadic basal-like cancers respond to platinum-based chemotherapy and are associated with a high rate of complete pathologic response [8, 37, 38] .
Given the high response rate of basal-like breast cancers to platinum-based therapy, our goal is to maximize the benefits associated with this type of therapy through drug combination strategies. Using a kinase inhibitor library, we identified six compounds that significantly potentiate the anti-proliferative effects of cisplatin in basal-like breast cancer cells. These compounds included rapamycin, LY36 4947, AG1478, BAY11-7082, LY294002, and SB203580, which target the mTOR, TGFbRI, NFjB, PI3K/AKT, and MAPK pathways, respectively. Out of the six compounds identified, rapamycin showed the strongest synergistic effects with cisplatin, while the others showed mainly additive effects. This result is consistent with other studies showing that inhibition of mTOR by RNAi or small molecules (e.g., rapamycin, CCI-779, and RAD001) enhances cisplatin chemosensitivity in ovarian [39] [40] [41] , endometrial [42] , head and neck [43] , lung [44] , skin [45, 46] , and liver [47] cancers.
We next compared the synergistic effects of cisplatinrapamycin combination in a panel of luminal-like and basallike breast cancer cell lines. Intriguingly, the synergistic effects were observed only in basal-like cells but not in the luminal-like cells. Several models have been proposed to explain the synergistic effects of the cisplatin-rapamycin combination in cancer cells. Beuvink et al. [48] showed that everolimus, a rapamycin derivative, dramatically enhances cisplatin-induced apoptosis in wild-type p53 but not mutant p53 tumor cells by inhibiting p53-induced p21 expression. Wangpaichitr et al. [49] demonstrated that inhibition of mTOR by CCI-779 decreases levels of the anti-apoptotic proteins BCL2 and BCLxL and increases the rate of apoptosis in cisplatin-resistant lung cancer cells. Although these models provide important evidence for synergy between mTOR inhibitors and cisplatin in cancer cells, they fail to explain the specific synergism observed in basal-like breast cancer cells, as the basal-like cells that we tested have p53 mutations and do not express high levels of BCL2 or BCLxL (data not shown). This led us to postulate that other signal transduction pathway that is inhibited by rapamycin may be an important component that leads to synergy with cisplatin and increases the chemosensitivity of basal-like cells. Because p73 has been reported to mediate cisplatin sensitivity in a subset of triple-negative breast cancer cells [4, 19, 20] and because inhibition of mTOR by rapamycin or RNAi has been shown to lead to up-regulation of p73 [18] , we postulated that activation of the p73 pathway might be important for the synergistic effects of rapamycin. To test the role of p73 in cisplatin-rapamycin synergism, we first evaluated the expression of p73 protein levels following treatment with cisplatin and rapamycin alone or in combination in a panel of breast cancer cell lines. The results showed that induction of p73 protein expression was observed in basal-like breast cancer cells but not in the luminal-like cells following treatment with rapamycin alone. When the basal-like MDA-MB-231, MDA-MB-468, and HCC1937 cells were treated with cisplatin-rapamycin, the elevation in the p73 expression and its pro-apoptotic target genes was significantly enhanced, corroborated with the synergism observed between cisplatin and rapamycin in these cell lines. In contrast, no such enhancement was observed in the luminal-like T47D and MCF-7 cells. The observed changes in p73 protein in MDA-MB-231 and MDA-MB-468 cells, however, were not due to parallel changes in p73 mRNA levels, suggesting that inhibition of mTOR may lead to inactivation of an as yet unknown p73-specific protein degradation pathway.
To validate that the cisplatin-rapamycin synergism was mediated by p73, we generated isogenic p73-depleted MDA-MB-231 and MDA-MB-468 cells using a lentiviral shRNA that specifically targeted the transactivating isoform of p73 (TAp73). Indeed, depletion of TAp73 in MDA-MB-231 and MDA-MB-468 cells completely abrogated the synergistic effects of cisplatin-rapamycin Fig. 6 The synergistic effects of rapamycin combined with cisplatin are completely ablated in TAp73-depleted cells. Doseresponse curve of vector control or TAp73-depleted MDA-MB-231 and MDA-MB-468 cells following treatment with cisplatin and/or rapamycin. Cell viability was determined using MTT assay 72 h after treatment. Points represent the mean ± SD of three independent experiments. Combination index (CI) was determined using isobologram analysis at ED 50 . A CI \ 1 indicates synergism, a CI = 1 indicates additivity, and a CI [ 1 indicates antagonism treatment, suggesting that the synergism between rapamycin and cisplatin requires the function of p73.
Although the combination of cisplatin and rapamycin for the treatment of breast cancer has not been previously investigated in a clinical study, it is worth noting that a phase II neo-adjuvant clinical trial of cisplatin and everolimus in patients with triple-negative breast cancer has recently opened for recruitment (ClinicalTrials.gov Identifier: NCT00930930) and will be able to directly address the potential of combination therapy with cisplatin and mTOR inhibitors. In conclusion, combination therapy with an mTOR inhibitor and cisplatin may be a useful approach for treating patients with basal-like breast cancers.
